LCZ696

• CAT Number: I005565
• CAS Number: 936623-90-4
• Molecular Formula: C48H54N6Na3O8.2.5H2O
• Molecular Weight: 956.99
• Purity: ≥95%
• Synonyms: LCZ-696
• Target: Angiotensin Receptor
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C

LCZ696 (Cat No.:I005565), also known as Sacubitril/Valsartan, is a first-in-class medication that combines the properties of an angiotensin II receptor blocker (ARB) and a neprilysin inhibitor. It contains molecular components of valsartan, an ARB, and AHU377, a prodrug of a neprilysin inhibitor. By blocking the angiotensin II receptor, LCZ696 helps to relax and widen blood vessels, reducing blood pressure and easing the workload on the heart. Additionally, neprilysin inhibition enhances the levels of beneficial peptides involved in cardiovascular regulation, leading to improved cardiac function. LCZ696 is primarily used for the treatment of heart failure with reduced ejection fraction, providing a novel therapeutic approach for managing this condition.

Reference

1:Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G.Clin Pharmacokinet. 2017 Apr 17. doi: 10.1007/s40262-017-0543-3. [Epub ahead of print] Review. PMID: 28417439
2:Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study. Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J.J Cardiovasc Pharmacol. 2017 Mar 23. doi: 10.1097/FJC.0000000000000485. [Epub ahead of print] PMID: 28338503
3:Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV.Eur Heart J. 2017 Apr 14;38(15):1132-1143. doi: 10.1093/eurheartj/ehw570. PMID: 28158398
4:Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model. Lin W, Ji T, Einolf H, Ayalasomayajula S, Lin TH, Hanna I, Heimbach T, Breen C, Jarugula V, He H.J Pharm Sci. 2017 May;106(5):1439-1451. doi: 10.1016/j.xphs.2017.01.007. Epub 2017 Jan 13. PMID: 28089685
5:Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. Wang JG, Yukisada K, Sibulo A Jr, Hafeez K, Jia Y, Zhang J.J Hypertens. 2017 Apr;35(4):877-885. doi: 10.1097/HJH.0000000000001219. PMID: 28030431
6:Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, Okino N, Guo W.J Cardiol. 2016 Dec 23. pii: S0914-5087(16)30309-4. doi: 10.1016/j.jjcc.2016.11.011. [Epub ahead of print] PMID: 28024961 Free Article
7:Sacubitril/Valsartan (LCZ696) in Heart Failure. Khder Y, Shi V, McMurray JJ, Lefkowitz MP.Handb Exp Pharmacol. 2016 Dec 22. doi: 10.1007/164_2016_77. [Epub ahead of print] PMID: 28004291
8:Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development. Hua Y, Wang I, Liu B, Kelly DJ, Reid C, Liew D, Zhou Y, Wang BH.Future Cardiol. 2017 Mar;13(2):103-115. doi: 10.2217/fca-2016-0057. Epub 2016 Nov 28. PMID: 27892684
9:Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, Pal P, Yang F, Hirschhorn E, Prescott MF, Hinder M, Langenickel TH.Hypertension. 2017 Jan;69(1):32-41. Epub 2016 Nov 14. PMID: 27849566
10:Effect of food on the oral bioavailability of the angiotensin receptor – neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
. Ayalasomayajula S, Langenickel TH, Chandra P, Wolfson ED, Albrecht D, Zhou W, Pal P, Rajman I, Sunkara G.Int J Clin Pharmacol Ther. 2016 Dec;54(12):1012-1018. PMID: 27719743